{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:10Z","timestamp":1793496070253,"version":"4.5.0"},"reference-count":224,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zambon SpA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Non-motor symptoms (NMSs) of Parkinson\u2019s disease (PD) were recognized by James Parkinson himself about 200 years ago and are now considered to be an integral part of PD, significantly contributing to the deterioration of patients\u2019 quality of life. Although awareness of NMSs is growing, and several scientific societies now have dedicated non-motor study groups, the NMS burden is still the hidden face of PD and in most cases, clinicians\u2019 views are focused on the motor symptoms alone. The literature was reviewed using several databases and scientific journals; this review provides a comprehensive description of the most common NMSs in PD, their clinical phenotype, social impact, diagnosis, and therapeutic management. Early recognition of these features may lead to more prompt and effective treatment and may help to better understand patients\u2019 needs.<\/jats:p>","DOI":"10.3390\/cells15010042","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T02:07:58Z","timestamp":1766714878000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Non-Motor Symptoms: The Hidden Face of Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7810-4514","authenticated-orcid":false,"given":"Carlo","family":"Cattaneo","sequence":"first","affiliation":[{"name":"Medical Department, Zambon SpA, 20091 Bresso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-0230","authenticated-orcid":false,"given":"Andrea","family":"Fabbrini","sequence":"additional","affiliation":[{"name":"Neurology Department, San Giovanni Hospital, 00153 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Belvisi","sequence":"additional","affiliation":[{"name":"Department Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy"},{"name":"Neurology Department, IRCSS Neuromed, 86077 Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Aiello","sequence":"additional","affiliation":[{"name":"Department Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8481-2155","authenticated-orcid":false,"given":"Francesco","family":"Marchet","sequence":"additional","affiliation":[{"name":"Neurology Department, IRCSS Neuromed, 86077 Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Fabbrini","sequence":"additional","affiliation":[{"name":"Department Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy"},{"name":"Neurology Department, IRCSS Neuromed, 86077 Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson\u2019s disease","volume":"391","author":"Tanner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factor in 195 countries and territories to 2050: Modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.28265","article-title":"Burden of Parkinson\u2019s disease by severity: Health care costs in the US Medicare population","volume":"36","author":"Dahodwala","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ncl.2024.12.008","article-title":"Non-motor symptoms and treatments in Parkinson\u2019s disease","volume":"43","author":"Goldman","year":"2025","journal-title":"Neurol. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/14737175.2021.1883428","article-title":"Non-motor complications in late-stage Parkinson\u2019s disease: Recognition, management and unmet needs","volume":"21","author":"Rukavina","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","article-title":"Unmet needs in Parkinsons disease: Motor and non-motor","volume":"80","author":"Lewitt","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.parkreldis.2019.04.014","article-title":"Barriers to reporting non-motor symptoms to health-care providers in people with Parkinson\u2019s","volume":"64","author":"Hurt","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/practneurol-2013-000741","article-title":"Non-motor Parkinson\u2019s: Integral to motor Parkinson\u2019s yet often neglected","volume":"14","author":"Todorova","year":"2014","journal-title":"Pract. Neurol."},{"key":"ref_9","first-page":"231","article-title":"Prevalence of non-motor symptoms and non-motor fluctuations in Parkinson\u2019s disease using the MDS-NMS","volume":"8","author":"Schrag","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_10","first-page":"160","article-title":"Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson\u2019s disease patients as assessed by the non-motor symptoms questionnaire","volume":"1","author":"Crosiers","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40120-024-00687-6","article-title":"Sex differences in Parkinson\u2019s disease: A narrative review","volume":"14","author":"Cattaneo","year":"2025","journal-title":"Neurol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clineuro.2014.10.006","article-title":"Non-motor fluctuations in Parkinson\u2019s disease: Prevalence, characteristics and management in a large cohort of parkinsonian outpatients","volume":"127","author":"Brun","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.irn.2023.11.001","article-title":"A general clinical overview of the non-motor symptoms in Parkinson\u2019s disease: Neuropsychiatric symptoms","volume":"174","author":"Batzu","year":"2024","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/bs.irn.2017.05.032","article-title":"Nonmotor symptoms in Parkinson\u2019s disease: Gender and ethnic differences","volume":"133","author":"Sauerbier","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00702-024-02833-8","article-title":"Non-motor symptoms of Parkinson\u2019s disease\u2014Insights from genetics","volume":"131","author":"Jercic","year":"2024","journal-title":"J. Neural Transm."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Liu, X., and Le, W. (2020). Profiling Non-motor Symptoms in Monogenic Parkinson\u2019s Disease. Front. Aging Neurosci., 12.","DOI":"10.3389\/fnagi.2020.591183"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/bmb\/ldad035","article-title":"Genetics in Parkinson\u2019s disease, state-of-the-art and future perspectives","volume":"149","author":"Trevisan","year":"2024","journal-title":"Br. Med. Bull."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/acn3.52244","article-title":"Clinical features and progression of Parkinson\u2019s disease with LLRK2 variants: A prospective study","volume":"12","author":"Song","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinsons\u2019 disease: Reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.irn.2017.01.009","article-title":"Genetics of Parkinson\u2019s Disease: Genotype-Phenotype Correlations","volume":"132","author":"Koros","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jes\u00fas, S., Huertas, I., Bernal-Bernal, I., Bonilla-Toribio, M., C\u00e1ceres-Redondo, M.T., Vargas-Gonz\u00e1lez, L., G\u00f3mez-Llamas, M., Carrillo, F., Calder\u00f3n, E., and Carballo, M. (2016). GBA Variants Influence Motor and Non-Motor Features of Parkinson\u2019s Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167749"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2217\/pgs-2020-0031","article-title":"The role of pharmacogenomics in the personalization of Parkinson\u2019s disease treatment","volume":"21","year":"2020","journal-title":"Pharmacogenomics"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Vuleti\u0107, V., Ra\u010dki, V., Papi\u0107, E., and Peterlin, B. (2021). A Systematic Review of Parkinson\u2019s Disease Pharmacogenomics: Is There Time for Translation into the Clinics?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137213"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1289\/ehp.1306967","article-title":"Research on the premotor symptoms of Parkinson\u2019s disease: Clinical and etiological implications","volume":"121","author":"Chen","year":"2013","journal-title":"Environ. Health Perspect."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: The inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson\u2019s disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/mds.25844","article-title":"Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson\u2019s disease","volume":"29","author":"Berg","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_29","first-page":"485063","article-title":"Dopamine-induced nonmotor symptoms of Parkinson\u2019s disease","volume":"2011","author":"Park","year":"2011","journal-title":"Park. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1100\/2011\/172893","article-title":"Serotonergic dysfunction in Parkinson\u2019s disease and its relevance to disability","volume":"11","author":"Politis","year":"2011","journal-title":"Sci. World J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Delaville, C., Deurwaerd\u00e8re, P.D., and Benazzouz, A. (2011). Noradrenaline and Parkinson\u2019s disease. Front. Syst. Neurosci., 5.","DOI":"10.3389\/fnsys.2011.00031"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/brain\/awh445","article-title":"Depression in Parkinson\u2019s disease: Loss of dopamine and noradrenaline innervation in the limbic system","volume":"128","author":"Remy","year":"2005","journal-title":"Brain"},{"key":"ref_33","first-page":"2","article-title":"The role of glutamate in the healthy brain and in the pathophysiology of Parkinson\u2019s disease","volume":"14","author":"Jenner","year":"2019","journal-title":"Eur. Neurol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11910-013-0377-9","article-title":"Cholinergic dysfunction in Parkinson\u2019s disease","volume":"13","author":"Bohnen","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/B978-0-443-19088-9.00001-9","article-title":"The involvement of the cholinergic system in Parkinson disease","volume":"211","author":"Pasquini","year":"2025","journal-title":"Handb. Clin. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40001-024-01779-7","article-title":"Role of GABA pathway in motor and non-motor symptoms in Parkinson\u2019s disease: A bidirectional circuit","volume":"29","author":"Alharbi","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Rizzi, G., and Tan, K.R. (2017). Dopamine and Acetylcholine, a Circuit Point of View in Parkinson\u2019s Disease. Front. Neural Circuits, 11.","DOI":"10.3389\/fncir.2017.00110"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1523\/JNEUROSCI.22-20-08785.2002","article-title":"Identification of the Nicotinic Receptor Subtypes Expressed on Dopaminergic Terminals in the Rat Striatum","volume":"22","author":"Zoli","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(18)30032-2","article-title":"The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson\u2019s disease: A cross-sectional PET study","volume":"17","author":"Liu","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.121.261939","article-title":"Striatal Acetylcholine\u2013Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET\u2013Informed Correlational Tractography","volume":"63","author":"Bohnen","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Paredes-Rodriguez, E., Vegas-Suarez, S., Morera-Herreras, T., De Deurwaerdere, P., and Miguelez, C. (2020). The Noradrenergic System in Parkinson\u2019s Disease. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00435"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Murueta-Goyena, A., Andikoetxea, A., G\u00f3mez-Esteban, J.C., and Gabilondo, I. (2019). Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson\u2019s Disease. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01294"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature11466","article-title":"Dopaminergic neurons inhibit striatal output via non-canonical release of GABA","volume":"490","author":"Tritsch","year":"2012","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1523\/JNEUROSCI.2289-15.2016","article-title":"Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson\u2019s Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study","volume":"36","author":"Yamasaki","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11910-017-0794-2","article-title":"PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson\u2019s Disease","volume":"17","author":"Pagano","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ana.24859","article-title":"Serotonin transporter in Parkinson\u2019s disease: A meta-analysis of positron emission tomography studies","volume":"81","author":"Pagano","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson\u2019s disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105697","DOI":"10.1016\/j.nbd.2022.105697","article-title":"Striatal glutamatergic hyperactivity in Parkinson\u2019s disease","volume":"168","author":"Campanelli","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","article-title":"Cholinergic system changes in Parkinson\u2019s disease: Emerging therapeutic approaches","volume":"21","author":"Bohnen","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/acschemneuro.6b00440","article-title":"Serotonergic Approaches in Parkinson\u2019s Disease: Translational Perspectives, an Update","volume":"8","author":"Huot","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbapap.2019.03.001","article-title":"Alpha-synuclein misfolding and aggregation: Implications in Parkinson\u2019s disease pathogenesis","volume":"1867","author":"Mehra","year":"2019","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"ref_52","unstructured":"Kahle, P., and Haass, C. (2004). Idiopathic Parkinson\u2019s disease: Staging an \u03b1 -synucleinopathy with a predictable pathoanatomy. Molecular Mechanisms in Parkinson\u2019s Disease, Landes Bioscience."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mds.23669","article-title":"Milestones in Parkinson\u2019s disease\u2014Clinical and pathologic features","volume":"26","author":"Halliday","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_55","first-page":"S257","article-title":"Defining Parkinson\u2019s disease: Past and future","volume":"14","author":"Kulcsarova","year":"2024","journal-title":"J. Park. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Global Parkinson\u2019s Disease Survey Steering Committee (2022). Factors impacting on quality of life in Parkinson\u2019s disease: Results from an international survey. Mov. Disord., 17, 60\u201367.","DOI":"10.1002\/mds.10010"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00391-021-01950-3","article-title":"Nonmotor symptoms and quality of life in Parkinson\u2019s disease with different motor subtypes","volume":"55","author":"Wu","year":"2022","journal-title":"Z. Gerontol. Geriatr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mds.27579","article-title":"The long-term direct and indirect economic burden among Parkinson\u2019s disease caregivers in the United States","volume":"34","author":"Macaulay","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2147\/NDT.S213917","article-title":"Impact of non-motor symptoms in Parkinson\u2019s disease: A PMDAlliance survey","volume":"15","author":"Hermanowicz","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/PROM.S160843","article-title":"Effects of Parkinson\u2019s on employment, cost of care, and quality of life of people with condition and family caregivers in the UK: A systematic literature review","volume":"10","author":"Gumber","year":"2019","journal-title":"Patient Relat. Outcome Meas."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","article-title":"Current and projected future economic burden of Parkinson\u2019s disease in the U.S","volume":"6","author":"Yang","year":"2020","journal-title":"NPJ Park. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/mds.10507","article-title":"Direct economic impact of Parkinson\u2019s disease: A research survey in the United Kingdom","volume":"18","author":"Findley","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_63","first-page":"5932675","article-title":"Cost of living with Parkinson\u2019s disease over 12 months in Australia: A prospective cohort study","volume":"2017","author":"Mudiyanselage","year":"2017","journal-title":"Park. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00415-025-13044-w","article-title":"The association between non-motor symptoms and cost in Parkinson\u2019s disease","volume":"272","author":"Gustafsson","year":"2025","journal-title":"J. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00702-024-02807-w","article-title":"Multidisciplinary care in Parkinson\u2019s disease","volume":"131","author":"Weise","year":"2024","journal-title":"J. Neural Transm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13063-019-3926-y","article-title":"The cost-effectiveness of specialized nursing interventions for people with Parkinson\u2019s disease: The NICE-PD study protocol for a randomized controlled clinical trial","volume":"21","author":"Radder","year":"2020","journal-title":"Trials"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.apnr.2014.12.008","article-title":"Support supplied by Parkinson\u2019s disease specialist nurses to Parkinson\u2019s disease patients and their spouses","volume":"28","author":"Hellqvist","year":"2015","journal-title":"Appl. Nurs. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12912-024-01931-y","article-title":"The role of nurses for patients with Parkinson\u2019s disease at home: A scoping review","volume":"23","author":"Fujita","year":"2024","journal-title":"BMS Nurs."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20844","article-title":"International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: The NMSQuest study","volume":"21","author":"Chaudhuri","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.21596","article-title":"The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: Results from an international pilot study","volume":"22","author":"Chaudhuri","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jnnp.2003.017509","article-title":"A short scale for the assessment of motor impairments and disabilities in Parkinson\u2019s disease: The SPES\/SCOPA","volume":"75","author":"Marinus","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society -sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF02260863","article-title":"The development and validation of a short measure of functioning and well-being for individuals with Parkinson\u2019s disease","volume":"4","author":"Peto","year":"1995","journal-title":"Qual. Life Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/mds.26270","article-title":"King\u2019s Parkinson\u2019s disease pain scale, the first scale for pain in PD: An international validation","volume":"30","author":"Chaudhuri","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/mds.23476","article-title":"Parkinson\u2019s disease sleep scale validation of the revised version PDSS-2","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: The Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch. Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.parkreldis.2004.07.007","article-title":"The Parkinson fatigue scale","volume":"11","author":"Brown","year":"2005","journal-title":"Park. Relat. Disord."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ene.13624","article-title":"Pain in Parkinson\u2019s disease: Facts and uncertainties","volume":"25","author":"Antonini","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_82","first-page":"63","article-title":"Pain in Parkinson\u2019s disease","volume":"5","author":"Ford","year":"1998","journal-title":"Clin. Neurosci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/j.pain.0000000000002107","article-title":"The Parkinson disease pain classification system: Results from an international mechanism-based classification approach","volume":"162","author":"Mylius","year":"2021","journal-title":"Pain"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"132","DOI":"10.31083\/j.jin2205132","article-title":"Pain in Parkinson\u2019s disease: Pathophysiology, classification and treatment","volume":"22","author":"Cattaneo","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"ref_85","first-page":"1451","article-title":"Pain fluctuations in Parkinson\u2019s disease and their association with motor and non-motor fluctuations","volume":"14","author":"Storch","year":"2024","journal-title":"J. Park. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(25)00033-X","article-title":"Advances in diagnosis, classification and management of pain in Parkinson\u2019s disease","volume":"24","author":"Tinazzi","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","article-title":"The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: Clinical cases and a review of the literature","volume":"90","author":"Pagonabarraga","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"120","DOI":"10.31083\/j.jin2104120","article-title":"Gender differences in pain subtypes among patients with Parkinson\u2019s disease","volume":"21","author":"Gao","year":"2022","journal-title":"J. Integr. Neurosci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.parkreldis.2019.06.001","article-title":"Young-onset Parkinson\u2019s disease: Its unique features and their impact on quality of life","volume":"65","author":"Mehanna","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"106257","DOI":"10.1016\/j.clineuro.2020.106257","article-title":"Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson\u2019s disease","volume":"199","author":"Eryilmaz","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.4238\/2015.May.12.14","article-title":"Association of CHRNA4 gene rs1044396 and rs1044397 polymorphisms with Parkinson\u2019s disease symptoms and smoking","volume":"14","author":"Zhang","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotorsymptoms of Parkinson\u2019s disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1113\/expphysiol.2012.069922","article-title":"The glutamatergic system as a target for neuropathic pain relief","volume":"98","author":"Osikowicz","year":"2013","journal-title":"Exp. Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000492221","article-title":"Comprehensive examination of therapies for pain in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"51","author":"Qureshi","year":"2018","journal-title":"Neuroepidemiology"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Santos Garc\u00eda, D., Y\u00e1\u00f1ez Ba\u00f1a, R., Labandeira Guerra, C., Cimas Hernando, M.I., Cabo L\u00f3pez, I., Paz Gonz\u00e1lez, J.M., Alonso Losada, M.G., Gonzalez Palm\u00e1s, M.J., Cores Bartolom\u00e9, C., and Mart\u00ednez Mir\u00f3, C. (2021). Pain improvement in Parkinson\u2019s disease patients treated with safinamide: Results from the SAFINONMOTOR study. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080798"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/neurolint12030014","article-title":"Chronic pain treatment strategies in Parkinsons\u2019 disease","volume":"12","author":"Edinoff","year":"2020","journal-title":"Neurol. Int."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pain.2008.04.026","article-title":"Comparison of chronic analgesic drugs prevalence in Parkinson\u2019s disease, other chronic diseases and the general population","volume":"141","author":"Grolleau","year":"2009","journal-title":"Pain"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.parkreldis.2020.07.006","article-title":"High-frequency repetitive transcranial magnetic stimulation over the primary motor cortex relieves musculoskeletal pain in patients with Parkinson\u2019s disease: A randomized controlled trial","volume":"80","author":"Li","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neurol.2023.04.010","article-title":"The effectiveness and safety of non-pharmacological intervention for pain management in Parkinson\u2019s disease: A systematic review","volume":"180","author":"Huissoud","year":"2024","journal-title":"Rev. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ana.20160","article-title":"Idiopathic hyposmia as a preclinical sign of Parkinson\u2019s disease","volume":"56","author":"Ponsen","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_101","first-page":"450939","article-title":"Olfactory loss in Parkinson\u2019s disease","volume":"2011","author":"Haehner","year":"2011","journal-title":"Park. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00415-006-0284-y","article-title":"Slective hyposmia and nigrostriatal dopaminergic denervation in Parkinson\u2019s disease","volume":"254","author":"Bohnen","year":"2007","journal-title":"J. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41531-025-00922-3","article-title":"Hyposmia in Parkinson\u2019s disease; exploring selective odour loss","volume":"11","author":"Mitchell","year":"2025","journal-title":"NPJ Park. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archneur.65.9.1237","article-title":"Phantosmias and Parkinson disease","volume":"65","author":"Landis","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"105567","DOI":"10.1016\/j.ebiom.2025.105567","article-title":"Evidence of alpha-synuclein aggregation in older individuals with hyposmia: A cross-sectional study","volume":"112","author":"Marek","year":"2025","journal-title":"EBioMedicine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/mds.10379","article-title":"Olfaction in neurodegenerative disorders","volume":"18","author":"Hawkes","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00401-010-0687-9","article-title":"Alpha-synucleinopathy in the human olfactory system in Parkinson\u2019s disease: Involvement of calcium-binding protein- and substance P-positive cells","volume":"119","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Nieto-Esamez, F., Obrero-Gaitan, E., and Cort\u00e9s-P\u00e9rez, I. (2023). Visual dysfunction in Parkinson\u2019s disease. Brain Sci., 13.","DOI":"10.3390\/brainsci13081173"},{"key":"ref_109","first-page":"1643","article-title":"Hallucinations and development of dementia in Parkinson\u2019s disease","volume":"10","author":"Gryc","year":"2020","journal-title":"J. Park. Dis."},{"key":"ref_110","first-page":"167","article-title":"Altered outer retinal structure, electrophysiology and visual perception in Parkinson\u2019s disease","volume":"14","author":"Tran","year":"2024","journal-title":"J. Park. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000523987","article-title":"The many faces of blurry vision in Parkinson\u2019s disease: An illustrative case series","volume":"14","author":"Borm","year":"2022","journal-title":"Case Rep. Neurol."},{"key":"ref_112","first-page":"785","article-title":"Self-reported visual complaints in people with Parkinson\u2019s disease: A systematic review","volume":"12","author":"Huizinga","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/cont.0000000000001562","article-title":"Symptomatic treatment of neuro-ophthalmic visual disturbances","volume":"31","author":"Kedar","year":"2025","journal-title":"Continuum"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"104749","DOI":"10.1016\/j.neubiorev.2022.104749","article-title":"Prevalence and clinical aspects of depression in Parkinson\u2019s disease: A systematic review and meta-analysis of 129 studies","volume":"141","author":"Cong","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Dujardin, K., and Sgambato, V. (2020). Neuropsychiatric disorders in Parkinson\u2019s disease: What do we know about the role of dopaminergic and non-dopaminergic systems?. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00025"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/jamaneurol.2023.4207","article-title":"Risk of suicidal ideation and behaviour in individuals with Parkinson disease: A systematic review and meta-analysis","volume":"81","author":"Mai","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/gps.4834","article-title":"Efficacy and tolerability of antidepressants in Parkinson\u2019s disease: A systematic review and network meta-analysis","volume":"33","author":"Mills","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: A randomized, double-bind, placebo-controlled trial","volume":"22","author":"Barone","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients","volume":"22","author":"Barone","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.3390\/biom5043112","article-title":"Overview of glutamatergic dysregulation in central pathologies","volume":"5","author":"Miladinovic","year":"2015","journal-title":"Biomolecules"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a, E., Borru\u00e9, C., Mata, M., Mart\u00ednez-Castrillo, J.C., Alonso-Canovas, A., Chico, J.L., L\u00f3pez-Manzanares, L., Llanero, M., Herreros-Rodr\u00edguez, J., and Esquivel, A. (2021). Impact of SAfinamide on Depressive symptoms in Parkinson\u2019s Disease patients (SADness-PD study): A multicenter retrospective study. Brain Sci., 11.","DOI":"10.3390\/brainsci11020232"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2174\/1570159X20666220315163856","article-title":"Advances in the pharmacological and non-pharmacological management of non-motor symptoms in Parkinson\u2019s disease: An update since 2017","volume":"21","author":"Wamelen","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/gps.5077","article-title":"Cognitive behavioral therapy improves diverse profiles of depressive symptoms in Parkinson\u2019s disease","volume":"34","author":"Dobkin","year":"2019","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mds.28335","article-title":"Electroconvulsive therapy for Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"36","author":"Takamiya","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jagp.2022.02.004","article-title":"Phenomenology of atypical anxiety disorders in Parkinson\u2019s disease: A systematic review","volume":"30","author":"Dissanayaka","year":"2022","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e41674","DOI":"10.1097\/MD.0000000000041674","article-title":"Advances in the study of depression and anxiety in Parkinson\u2019s disease: A review","volume":"104","author":"Wang","year":"2025","journal-title":"Medicine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/08919887211018267","article-title":"Mood disorders and anxiety in Parkinson\u2019s disease: Current concepts","volume":"34","author":"Lintel","year":"2021","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1176\/appi.neuropsych.20110272","article-title":"Anxiety in Parkinson\u2019s disease: A systematic review of neuroimaging studies","volume":"33","author":"Perepezko","year":"2021","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jagp.2021.02.037","article-title":"Optimal treatment of depression and anxiety in Parkinson\u2019s disease","volume":"29","author":"Pontone","year":"2021","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/mds.28533","article-title":"Cognitive behavioral therapy for anxiety in Parkinson\u2019s disease: A randomized controlled trial","volume":"36","author":"Moonen","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Bereau, M., Van Waes, V., Servant, M., Magnin, E., Tatu, L., and Anheim, M. (2023). Apathy in Parkinson\u2019s disease: Clinical patterns and neurobiological basis. Cells, 12.","DOI":"10.3390\/cells12121599"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/alz.12358","article-title":"Diagnostic criteria for apathy in neurocognitive disorders","volume":"17","author":"Miller","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-022-28892-7","article-title":"Medial prefrontal cortex and anteromedial thalamus interaction regulates goal-directed behavior and dopaminergic neuron activity","volume":"13","author":"Yang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1007\/s00415-024-12233-3","article-title":"Anatomical correlates of apathy and impulsivity co-occurrence in early Parkinson\u2019s disease","volume":"271","author":"Maggi","year":"2024","journal-title":"J. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e70019","DOI":"10.1111\/ejn.70019","article-title":"Unilateral and Bilateral Subthalamic Deep Brain Stimulation Differently Favour Apathy in Parkinson\u2019s Disease","volume":"61","author":"Vachez","year":"2025","journal-title":"Eur. J. Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e037632","DOI":"10.1136\/bmjopen-2020-037632","article-title":"Diagnosis, treatment and management of apathy in Parkinson\u2019s disease: A scoping review","volume":"10","author":"Mele","year":"2020","journal-title":"BMJ Open"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/s41386-020-0760-6","article-title":"Glutamine-to-Glutamate ratio in the nucleus accumbens predicts effort based motivated performance in humans","volume":"45","author":"Strasser","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Kulisevsky, J., Mart\u00ednez-Horta, S., Campolongo, A., Pascual-Sedano, B., Mar\u00edn-Lahoz, J., Bejr-Kasem, H., Aracil-Bola\u00f1os, I., Horta-Barba, A., Puig-Davi, A., and Pagonabarraga, J. (2022). A randomized clinical trial to evaluate the effects of safinamide on apathetic non-demented patients with Parkinson\u2019s disease. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.866502"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","article-title":"Rivastigmine in apathetic but dementia and depression-free patients with Parkinson\u2019s disease: A double-blind, placebo-controlled, randomized clinical trial","volume":"85","author":"Devos","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_140","first-page":"100096","article-title":"Non-pharmacologic interventions to treat apathy in Parkinson\u2019s disease: A realist review","volume":"4","author":"Mele","year":"2021","journal-title":"Clin. Park. Relat. Disord."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cger.2020.01.001","article-title":"Cognitive impairment and dementia in Parkinson\u2019s disease","volume":"36","author":"Goldman","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/mds.27665","article-title":"Modifiable risk factors for cognitive impairment in Parkinson\u2019s disease: A systematic review and meta-analysis of prospective cohort studies","volume":"34","author":"Guo","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid \u03b2 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"ref_145","first-page":"e827","article-title":"Nfl as a biomarker for neurodegeneration and survival in Parkinson disease","volume":"95","author":"Linder","year":"2020","journal-title":"Neurology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1111\/ene.15481","article-title":"Systematic review of data-driven cognitive subtypes in Parkinson disease","volume":"29","author":"Pourzinal","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/00207454.2019.1667799","article-title":"Noradrenergic pathways of locus coeruleus in Parkinson\u2019s and Alzheimer\u2019s pathology","volume":"130","author":"Singh","year":"2020","journal-title":"Int. J. Neurosci."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Sun, C., and Armstrong, M.J. (2021). Treatment of Parkinson\u2019s disease with cognitive impairment: Current approaches and future directions. Behav. Sci., 11.","DOI":"10.3390\/bs11040054"},{"key":"ref_149","first-page":"4853590","article-title":"Atomoxetine does not improve complex attention in idiopathic Parkinson\u2019s disease patients with cognitive deficits: A meta-analysis","volume":"2020","author":"Ghosh","year":"2020","journal-title":"Park. Dis."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liu, S., Xu, K., Zhou, Y., Shen, Y., Liu, Z., Bai, Y., and Wang, S. (2024). Non-pharmacological therapies for treating non-motor symptoms in patients with Parkinson\u2019s disease: A systematic review and meta-analysis. Front. Aging Neurosci., 16.","DOI":"10.3389\/fnagi.2024.1363115"},{"key":"ref_151","first-page":"85","article-title":"Frequency and characteristics of psychosis in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"12","author":"Chendo","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-023-00918-8","article-title":"Parkinson disease psychosis: From phenomenology to neurobiological mechanisms","volume":"20","author":"Pagonabarraga","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/13607863.2025.2450258","article-title":"Paranoid and unusual sensory experiences in Parkinson\u2019s disease","volume":"29","author":"Brown","year":"2025","journal-title":"Aging Ment. Health"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"fcae358","DOI":"10.1093\/braincomms\/fcae358","article-title":"Functional and connectivity correlates associated with Parkinson\u2019s disease psychosis: A systematic review","volume":"6","author":"Pisani","year":"2024","journal-title":"Brain Commun."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Komagamine, T., Suzuki, K., Kokubun, N., Komagamine, J., Kawasaki, A., Funakoshi, K., and Hirata, K. (2022). Sleep-related hallucinations in patients with Parkinson\u2019s disease. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0276736"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archneur.61.8.1280","article-title":"Genetic polymorphisms in Parkinson\u2019s disease subjects with and without hallucinations: An analysis of the cholecystokinin system","volume":"61","author":"Goldman","year":"2004","journal-title":"Arch. Neurol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/08919887211018280","article-title":"Psychosis in Parkinson\u2019s disease: Current treatment options and impact on patients and caregivers","volume":"34","author":"Segal","year":"2021","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5498\/wjp.v9.i3.47","article-title":"Evidence for using pimavanserin for the treatment of Parkinson\u2019s disease psychosis","volume":"9","author":"Tampi","year":"2019","journal-title":"World J. Psychiatry"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Rose, O., Huber, S., Trinka, E., Pachmayr, J., Clemens, S., Pachmayr, J., and Clemens, S. (2024). Treatment of Parkinson\u2019s disease psychosis\u2014A systematic review and multi-methods approach. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102317"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00702-024-02846-3","article-title":"Behavioral disorders in Parkinson\u2019s disease: Current view","volume":"132","author":"Jellinger","year":"2025","journal-title":"J. Neural Transm."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Zhang, J.F., Wang, X.X., Feng, Y., Fekete, R., Jankovic, J., and Wu, Y.C. (2021). Impulse control disorders in Parkinson\u2019s disease: Epidemiology, pathogenesis and therapeutic strategies. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.635494"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00702-023-02735-1","article-title":"Morphometric alterations of the mesocorticolimbic network in Parkinson\u2019s disease with impulse control disorders","volume":"131","author":"Ansari","year":"2024","journal-title":"J. Neural Transm."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/mp.2009.95","article-title":"Insights into pathophysiology of punding reveal possible treatment strategies","volume":"15","author":"Fasano","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/mdc3.13748","article-title":"Punding in Parkinson\u2019s Disease: An Update","volume":"10","author":"Rajalingam","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cger.2019.09.005","article-title":"Overview of sleep and circadian rhythm disorders in Parkinson disease","volume":"36","author":"Gros","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.sleep.2021.02.036","article-title":"Sleep problems affect quality of life in Parkinson\u2019s disease along disease progression","volume":"81","author":"Liguori","year":"2021","journal-title":"Sleep Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jsmc.2023.10.004","article-title":"Rapid eye movement sleep behavior disorder: Clinical presentation and diagnostic criteria","volume":"19","author":"Jones","year":"2024","journal-title":"Sleep. Med. Clin."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"zsad030","DOI":"10.1093\/sleep\/zsad030","article-title":"Rapid eye movement sleep behavior disorder: A narrative review from a technological perspective","volume":"46","author":"Gnarra","year":"2023","journal-title":"Sleep"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e13966","DOI":"10.1111\/apha.13966","article-title":"Sleep and circadian rhythms in \u03b1-synucleinopathies-Perspectives for disease modification","volume":"238","author":"Kunz","year":"2023","journal-title":"Acta Physiol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"759","DOI":"10.5664\/jcsm.10424","article-title":"Management of REM sleep behavior disorder: An American Academy of Sleep Medicine clinical practice guideline","volume":"19","author":"Howell","year":"2023","journal-title":"J. Clin. Sleep Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"107103","DOI":"10.1016\/j.parkreldis.2024.107103","article-title":"Safinamide effect on sleep architecture of motor fluctuating Parkinson\u2019s disease patients: A polysomnographic rasagiline-controlled study","volume":"127","author":"Bovenzi","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s13311-020-00938-y","article-title":"Sleep issues in Parkinson\u2019s disease and their management","volume":"17","author":"During","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14737175.2025.2450789","article-title":"Managing sleep issues in Parkinson\u2019s disease: An up-to-date review","volume":"25","author":"Suzuki","year":"2025","journal-title":"Expert Rev. Neurother."},{"key":"ref_174","first-page":"1339","article-title":"Restless legs symptoms and periodic leg movements in sleep among patients with Parkinson\u2019s disease","volume":"12","author":"Bliwise","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.sleep.2024.07.015","article-title":"Prevalence and clinical profile of patients with restless legs syndrome in Parkinson\u2019s disease: A meta-analysis","volume":"121","author":"Maggi","year":"2024","journal-title":"Sleep Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11940-019-0596-8","article-title":"Therapies for restless legs in Parkinson\u2019s disease","volume":"21","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"101759","DOI":"10.1016\/j.smrv.2023.101759","article-title":"Sleep and wakefulness disturbances in Parkinson\u2019s disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia","volume":"68","author":"Maggi","year":"2023","journal-title":"Sleep Med. Rev."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/0118715273314675240820191447","article-title":"Sleep-related disorders in Parkinson\u2019s disease: Mechanisms, diagnosis, and therapeutic approaches","volume":"24","author":"Hamid","year":"2025","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1586\/ern.10.56","article-title":"Narcolepsy in Parkinson\u2019s disease","volume":"10","author":"Haq","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neuron.2010.11.032","article-title":"Sleep state switching","volume":"68","author":"Saper","year":"2010","journal-title":"Neuron"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00062-022-01190-x","article-title":"Excessive daytime sleepiness in Parkinson\u2019s disease is related to functional abnormalities in the left angular gyrus","volume":"33","author":"Zheng","year":"2023","journal-title":"Clin. Neuroradiol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s10072-024-07422-x","article-title":"Impact of autonomic symptoms on the clinical course of Parkinson\u2019s disease","volume":"45","author":"Fujita","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Li, F.F., Cui, Y.S., Yan, R., Cao, S.S., and Feng, T. (2022). Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson\u2019s disease: A systematic review and meta-analysis. Front. Aging Neurosci., 14.","DOI":"10.3389\/fnagi.2022.977572"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease","volume":"24","author":"Barone","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/1520-6777(2001)20:1<105::AID-NAU12>3.0.CO;2-9","article-title":"Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats","volume":"20","author":"Seki","year":"2001","journal-title":"Neurourol. Urodyn."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"104700","DOI":"10.1016\/j.nbd.2019.104700","article-title":"Autonomic dysfunction in Parkinson\u2019s disease: Implications for pathophysiology, diagnosis, and treatment","volume":"134","author":"Chen","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Hu, J.C., Hsu, L.N., Lee, W.C., Chuang, Y.C., and Wang, H.J. (2023). Role of urological botulinum toxin-A injection for overactive bladder and voiding dysfunction in patients with Parkinson\u2019s disease or post-stroke. Toxins, 15.","DOI":"10.3390\/toxins15020166"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-L\u00f3pez, A., S\u00e1nchez-S\u00e1nchez, A., Natera-Villalba, E., Ros-Castell\u00f3, V., Beltr\u00e1n-Corbellini, \u00c1., Fanjul-Arb\u00f3s, S., Pare\u00e9s Moreno, I., L\u00f3pez-Sendon Moreno, J.L., Mart\u00ednez Castrillo, J.C., and Alonso-Canovas, A. (2021). SURINPARK: Safinamide for urinary symptoms in Parkinson\u2019s disease. Brain Sci., 11.","DOI":"10.3390\/brainsci11010057"},{"key":"ref_189","first-page":"S81","article-title":"Non-pharmacological treatment of autonomic dysfunction in Parkinson\u2019s disease and other synucleinopathies","volume":"14","author":"Palma","year":"2024","journal-title":"J. Park. Dis."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40265-021-01664-1","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"82","author":"Safarpour","year":"2022","journal-title":"Drugs"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10571-021-01066-7","article-title":"The gut-brain axis: Two ways signaling in Parkinson\u2019s disease","volume":"42","author":"Dogra","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Isaacson, J., Patel, S., Torres-Yaghi, Y., and Pag\u00e1n, F. (2020). Sialorrhea in Parkinson\u2019s disease. Toxins, 12.","DOI":"10.3390\/toxins12110691"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00784-023-04981-9","article-title":"Effectiveness of the pharmacological treatments for sialorrhea in patients with Parkinson\u2019s disease: A systematic review and network meta-analysis","volume":"27","author":"Santos","year":"2023","journal-title":"Clin. Oral Investig."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2169\/internalmedicine.2373-18","article-title":"Management of dysphagia in patients with Parkinson\u2019s disease and related disorders","volume":"59","author":"Umemoto","year":"2020","journal-title":"Intern. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"120008","DOI":"10.1016\/j.jns.2021.120008","article-title":"Consensus on the treatment of dysphagia in Parkinson\u2019s disease","volume":"430","author":"Schindler","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.parkreldis.2020.05.001","article-title":"Clinical implications of gastric complications on levodopa treatment in Parkinson\u2019s disease","volume":"76","author":"Pfeiffer","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Soliman, H., Coffin, B., and Gourcerol, G. (2021). Gastroparesis in Parkinson disease: Pathophysiology, and clinical management. Brain Sci., 11.","DOI":"10.3390\/brainsci11070831"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000527513","article-title":"Constipation in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"86","author":"Yao","year":"2023","journal-title":"Eur. Neurol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/JNN.0000000000000611","article-title":"Constipation management in Parkinson disease","volume":"53","author":"Cheesman","year":"2021","journal-title":"J. Neurosci. Nurs."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"e14767","DOI":"10.1111\/nmo.14767","article-title":"Defecatory disorders are a common cause of chronic constipation in Parkinson disease","volume":"36","author":"Ramu","year":"2024","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cger.2019.09.002","article-title":"Orthostatic hypotension in Parkinson disease","volume":"36","author":"Palma","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Grosu, C., Noea, O., Ma\u0219taleru, A., Ignat, E.B., and Leon, M.M. (2025). Neurogenic orthostatic hypotension in Parkinson disease-a narrative review of diagnosis and management. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020630"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1509723","article-title":"Baroreflex dysfunction","volume":"382","author":"Kaufmann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_204","first-page":"S57","article-title":"Management of orthostatic hypotension in Parkinson\u2019s disease","volume":"10","author":"Fanciulli","year":"2020","journal-title":"J. Park. Dis."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.irn.2021.12.001","article-title":"Prevalence, clinical presentations and impact on relationship of sexual dysfunction in Parkinson\u2019s Disease","volume":"162","author":"Buhmann","year":"2022","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.irn.2022.01.001","article-title":"The pathophysiology of sexual dysfunction in Parkinson\u2019s disease: An overview","volume":"162","author":"Batzu","year":"2022","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.irn.2021.12.004","article-title":"Management strategies of sexual dysfunctions in Parkinson\u2019s disease","volume":"162","author":"Urso","year":"2022","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/mdc3.12456","article-title":"Sildenafil in the treatment of erectile dysfunction in Parkinson\u2019s Disease","volume":"4","author":"Bernard","year":"2016","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_209","first-page":"e81129","article-title":"Exploring fatigue in Parkinson\u2019s Disease: A comprehensive literature review","volume":"17","author":"Jayasinghe","year":"2025","journal-title":"Cureus"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002512-200926030-00002","article-title":"Physical and mental fatigue in Parkinson\u2019s disease: Epidemiology, pathophysiology and treatment","volume":"26","author":"Lou","year":"2009","journal-title":"Drugs Aging"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00702-019-02130-9","article-title":"Neural and dopaminergic correlates of fatigue in Parkinson\u2019s disease","volume":"127","author":"Kang","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.30214","article-title":"Molecular-informed network analysis unveils fatigue-related functional connectivity in Parkinson\u2019s disease","volume":"40","author":"Moretto","year":"2025","journal-title":"Mov. Disord."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/brain\/awq268","article-title":"Fatigue in Parkinson\u2019s disease is linked to striatal and limbic serotonergic dysfunction","volume":"133","author":"Pavese","year":"2010","journal-title":"Brain"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"106844","DOI":"10.1016\/j.clineuro.2021.106844","article-title":"Possible inflammatory mechanisms and predictors of Parkinson\u2019s disease patients with fatigue (brief review)","volume":"208","author":"Wang","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"578222","DOI":"10.1016\/j.jneuroim.2023.578222","article-title":"Plasma TNF-\u03b1 and phosphorylated \u03b1-syn are associated with fatigue in patients with Parkinson\u2019s disease","volume":"385","author":"Wang","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.clinph.2021.03.001","article-title":"Intracortical GABAergic dysfunction in patients with fatigue and dysexecutive syndrome after COVID-19","volume":"132","author":"Versace","year":"2021","journal-title":"Clin. Neurophysiol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jnnp-2012-302402","article-title":"A clinical and family history study of Parkinson\u2019s disease in heterozygous glucocerebrosidase mutation carriers","volume":"83","author":"McNeill","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.parkreldis.2017.09.016","article-title":"Fatigue correlates with LRRK2 G2385R variant in Chinese Parkinson\u2019s disease patients","volume":"44","author":"Fu","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/aomd.aomd_99_24","article-title":"Fatigue in Parkinson\u2019s disease\u2014A narrative review","volume":"7","author":"Panigrahi","year":"2024","journal-title":"Ann. Mov. Disord."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s10072-024-07985-9","article-title":"Pain and fatigue in Parkinson\u2019s disease: Advances in diagnosis and management","volume":"46","author":"Tinazzi","year":"2025","journal-title":"Neurol. Sci."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00702-023-02654-1","article-title":"Fatigue in fluctuating Parkinson\u2019s disease patients: Possible impact of safinamide","volume":"130","author":"Pauletti","year":"2023","journal-title":"J. Neural Transm."},{"key":"ref_222","first-page":"769506","article-title":"The prevalence of fatigue following deep brain stimulation surgery in Parkinson\u2019s disease and association with quality of life","volume":"2012","author":"Kluger","year":"2012","journal-title":"Park. Dis."},{"key":"ref_223","first-page":"659","article-title":"Physical exercise as a potential treatment for fatigue in Parkinson\u2019s disease? A systematic review and meta-analysis of pharmacological and non-pharmacological interventions","volume":"13","author":"Folkerts","year":"2023","journal-title":"J. Park. Dis."},{"key":"ref_224","first-page":"393","article-title":"Dietary patterns and nonmotor symptoms in Parkinson\u2019s disease: A cross-sectional analysis","volume":"42","author":"Lawrie","year":"2023","journal-title":"J. Am. Nutr. Assoc."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/1\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T02:20:55Z","timestamp":1766715655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/1\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cells15010042"],"URL":"https:\/\/doi.org\/10.3390\/cells15010042","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]}}}